4.7 Article

Activating mutations in human acute megakaryoblastic leukemia

期刊

BLOOD
卷 112, 期 10, 页码 4220-4226

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-01-136366

关键词

-

资金

  1. Association pour la Recherche sur le Cancer (ARC)
  2. Institut National du Cancer (INCa)
  3. Fonds National de la Recherche Scientifique
  4. Fondation contre le cancer
  5. Fondation Salus Sanguinis
  6. University catholique de Louvain, Brussels [MEXP31C1]
  7. Fondation contre le Cancer, Brussels
  8. PAI Program Belgium [BCHM61B5]
  9. Atlantic Philantropies/Ludwig Institute for Cancer Research Clinical Discoveries Program
  10. Fondation pour la Recherche Medicale and Societe Francaise d' Hematologie

向作者/读者索取更多资源

Oncogenic activation of tyrosine kinase signaling pathway is recurrent in human leukemia. To gain insight into the oncogenic process leading to acute megakaryoblastic leukemia (AMKL), we performed sequence analyses of a subset of oncogenes known to be activated in human myeloid and myeloproliferative disorders. In a series of human AMKL samples from both Down syndrome and non-Down syndrome patients, mutations were identified within KIT, FLT3, JAK2, JAK3, and MPL genes, with a higher frequency in DS than in non-DS patients. The novel mutations were analyzed using BaF3 cells, showing that JAK3 mutations were activating mutations. Finally, we report a novel constitutively active MPL mutant, MPLT487A, observed in a non Down syndrome childhood AMKL that induces a myeloproliferative disease in mouse bone marrow transplantation assay. (Blood. 2008; 112: 4220-4226)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据